Clinical Trial Update: Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating cariprazine in a dose-reduction strategy for relapse prevention in schizophrenia was terminated; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• cariprazine (cariprazine)

Snippet

Sponsor: AbbVie | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED | Results posted: 2022-03-08